Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2015

01.08.2015 | Preclinical study

Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density

verfasst von: G. L. Chew, C. W. Huo, D. Huang, P. Hill, J. Cawson, H. Frazer, J. L. Hopper, I. Haviv, M. A. Henderson, K. Britt, E. W. Thompson

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Mammographic density (MD) adjusted for age and body mass index is one of the strongest known risk factors for breast cancer. Given the high attributable risk of MD for breast cancer, chemoprevention with a safe and available agent that reduces MD and breast cancer risk would be beneficial. Cox-2 has been implicated in MD-related breast cancer risk, and was increased in stromal cells in high MD tissues in one study. Our study assessed differential Cox-2 expression in epithelial and stromal cells in paired samples of high and low MD human breast tissue, and in a validated xenograft biochamber model of MD. We also examined the effects of endocrine treatment upon Cox-2 expression in high and low MD tissues in the MD xenograft model. Paired high and low MD human breast tissue samples were immunostained for Cox-2, then assessed for differential expression and staining intensity in epithelial and stromal cells. High and low MD human breast tissues were separately maintained in biochambers in mice treated with Tamoxifen, oestrogen or placebo implants, then assessed for percentage Cox-2 staining in epithelial and stromal cells. Percentage Cox-2 staining was greater for both epithelial (p = 0.01) and stromal cells (p < 0.0001) of high compared with low MD breast tissues. In high MD biochamber tissues, percentage Cox-2 staining was greater in stromal cells of oestrogen-treated versus placebo-treated tissues (p = 0.05).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, Thompson EW (2014) Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat 144(3):479–502. doi:10.1007/s10549-014-2901-2 CrossRefPubMed Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, Thompson EW (2014) Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat 144(3):479–502. doi:10.​1007/​s10549-014-2901-2 CrossRefPubMed
4.
Zurück zum Zitat Baglietto L, Krishnan K, Stone J, Apicella C, Southey MC, English DR, Hopper JL, Giles GG (2014) Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. Am J Epidemiol 179(4):475–483. doi:10.1093/aje/kwt260 CrossRefPubMed Baglietto L, Krishnan K, Stone J, Apicella C, Southey MC, English DR, Hopper JL, Giles GG (2014) Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. Am J Epidemiol 179(4):475–483. doi:10.​1093/​aje/​kwt260 CrossRefPubMed
5.
Zurück zum Zitat Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Czene K, Darabi H, Eriksson M, Peto J, Dos-Santos-Silva I, Dudbridge F, Johnson N, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Couch FJ, Olson JE, Vachon C, Pankratz VS, Lambrechts D, Wildiers H, Van Ongeval C, van Limbergen E, Kristensen V, Grenaker Alnaes G, Nord S, Borresen-Dale AL, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Trentham-Dietz A, Newcomb P, Titus L, Egan KM, Hunter DJ, Lindstrom S, Tamimi RM, Kraft P, Rahman N, Turnbull C, Renwick A, Seal S, Li J, Liu J, Humphreys K, Benitez J, Pilar Zamora M, Arias Perez JI, Menendez P, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Bogdanova NV, Antonenkova NN, Dork T, Anton-Culver H, Neuhausen SL, Ziogas A, Bernstein L, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Cox A, Cross SS, Reed MW, Khusnutdinova E, Bermisheva M, Prokofyeva D, Takhirova Z, Meindl A, Schmutzler RK, Sutter C, Yang R, Schurmann P, Bremer M, Christiansen H, Park-Simon TW, Hillemanns P, Guenel P, Truong T, Menegaux F, Sanchez M, Radice P, Peterlongo P, Manoukian S, Pensotti V, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Brauch H, Bruning T, Ko YD, Sigurdson AJ, Doody MM, Hamann U, Torres D, Ulmer HU, Forsti A, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Andrulis IL, Knight JA, Glendon G, Marie Mulligan A, Chenevix-Trench G, Balleine R, Giles GG, Milne RL, McLean C, Lindblom A, Margolin S, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Eilber U, Wang-Gohrke S, Hooning MJ, Hollestelle A, van den Ouweland AM, Koppert LB, Carpenter J, Clarke C, Scott R, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Brenner H, Arndt V, Stegmaier C, Karina Dieffenbach A, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Offit K, Vijai J, Robson M, Rau-Murthy R, Dwek M, Swann R, Annie Perkins K, Goldberg MS, Labreche F, Dumont M, Eccles DM, Tapper WJ, Rafiq S, John EM, Whittemore AS, Slager S, Yannoukakos D, Toland AE, Yao S, Zheng W, Halverson SL, Gonzalez-Neira A, Pita G, Rosario Alonso M, Alvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, Simard J, Hall P, Easton DF, Garcia-Closas M (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107(5):djv036. doi:10.1093/jnci/djv036 CrossRefPubMed Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Czene K, Darabi H, Eriksson M, Peto J, Dos-Santos-Silva I, Dudbridge F, Johnson N, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Couch FJ, Olson JE, Vachon C, Pankratz VS, Lambrechts D, Wildiers H, Van Ongeval C, van Limbergen E, Kristensen V, Grenaker Alnaes G, Nord S, Borresen-Dale AL, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Trentham-Dietz A, Newcomb P, Titus L, Egan KM, Hunter DJ, Lindstrom S, Tamimi RM, Kraft P, Rahman N, Turnbull C, Renwick A, Seal S, Li J, Liu J, Humphreys K, Benitez J, Pilar Zamora M, Arias Perez JI, Menendez P, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Bogdanova NV, Antonenkova NN, Dork T, Anton-Culver H, Neuhausen SL, Ziogas A, Bernstein L, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Cox A, Cross SS, Reed MW, Khusnutdinova E, Bermisheva M, Prokofyeva D, Takhirova Z, Meindl A, Schmutzler RK, Sutter C, Yang R, Schurmann P, Bremer M, Christiansen H, Park-Simon TW, Hillemanns P, Guenel P, Truong T, Menegaux F, Sanchez M, Radice P, Peterlongo P, Manoukian S, Pensotti V, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Brauch H, Bruning T, Ko YD, Sigurdson AJ, Doody MM, Hamann U, Torres D, Ulmer HU, Forsti A, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Andrulis IL, Knight JA, Glendon G, Marie Mulligan A, Chenevix-Trench G, Balleine R, Giles GG, Milne RL, McLean C, Lindblom A, Margolin S, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Eilber U, Wang-Gohrke S, Hooning MJ, Hollestelle A, van den Ouweland AM, Koppert LB, Carpenter J, Clarke C, Scott R, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Brenner H, Arndt V, Stegmaier C, Karina Dieffenbach A, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Offit K, Vijai J, Robson M, Rau-Murthy R, Dwek M, Swann R, Annie Perkins K, Goldberg MS, Labreche F, Dumont M, Eccles DM, Tapper WJ, Rafiq S, John EM, Whittemore AS, Slager S, Yannoukakos D, Toland AE, Yao S, Zheng W, Halverson SL, Gonzalez-Neira A, Pita G, Rosario Alonso M, Alvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, Simard J, Hall P, Easton DF, Garcia-Closas M (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107(5):djv036. doi:10.​1093/​jnci/​djv036 CrossRefPubMed
6.
Zurück zum Zitat Hopper JL (2015) Odds PER Adjusted standard deviation (OPERA): comparing strengths of associations for risk factors measured on different scales, and across diseases and populations. Am J Epidemiol. doi:10.1093/aje/kwv193 Hopper JL (2015) Odds PER Adjusted standard deviation (OPERA): comparing strengths of associations for risk factors measured on different scales, and across diseases and populations. Am J Epidemiol. doi:10.​1093/​aje/​kwv193
7.
Zurück zum Zitat Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, Lingle WL, Odogwu T, Radisky DC, Visscher DW, Ingle JN, Hartmann LC, Vachon CM (2012) Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat 131(1):267–275. doi:10.1007/s10549-011-1727-4 PubMedCentralCrossRefPubMed Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, Lingle WL, Odogwu T, Radisky DC, Visscher DW, Ingle JN, Hartmann LC, Vachon CM (2012) Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat 131(1):267–275. doi:10.​1007/​s10549-011-1727-4 PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Lin SJ, Cawson J, Hill P, Haviv I, Jenkins M, Hopper JL, Southey MC, Campbell IG, Thompson EW (2011) Image-guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue. Breast Cancer Res Treat 128(2):505–516. doi:10.1007/s10549-011-1346-0 CrossRefPubMed Lin SJ, Cawson J, Hill P, Haviv I, Jenkins M, Hopper JL, Southey MC, Campbell IG, Thompson EW (2011) Image-guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue. Breast Cancer Res Treat 128(2):505–516. doi:10.​1007/​s10549-011-1346-0 CrossRefPubMed
9.
Zurück zum Zitat Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomark Prev 14(2):343–349. doi:10.1158/1055-9965.EPI-04-0490 CrossRef Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomark Prev 14(2):343–349. doi:10.​1158/​1055-9965.​EPI-04-0490 CrossRef
10.
Zurück zum Zitat Huo CW, Chew G, Hill P, Huang D, Ingman W, Hodson L, Brown KA, Magenau A, Allam AH, McGhee E, Timpson P, Henderson MA, Thompson EW, Britt K (2015) High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. Breast Cancer Res 17(1):79. doi:10.1186/s13058-015-0592-1 PubMedCentralCrossRefPubMed Huo CW, Chew G, Hill P, Huang D, Ingman W, Hodson L, Brown KA, Magenau A, Allam AH, McGhee E, Timpson P, Henderson MA, Thompson EW, Britt K (2015) High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. Breast Cancer Res 17(1):79. doi:10.​1186/​s13058-015-0592-1 PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103(9):744–752. doi:10.1093/jnci/djr079 CrossRefPubMed Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103(9):744–752. doi:10.​1093/​jnci/​djr079 CrossRefPubMed
14.
Zurück zum Zitat Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89(12):2637–2645CrossRefPubMed Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89(12):2637–2645CrossRefPubMed
15.
Zurück zum Zitat Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635PubMed Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635PubMed
16.
Zurück zum Zitat Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62(6):1676–1681PubMed Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62(6):1676–1681PubMed
17.
Zurück zum Zitat Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277(21):18649–18657. doi:10.1074/jbc.M111415200 CrossRefPubMed Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277(21):18649–18657. doi:10.​1074/​jbc.​M111415200 CrossRefPubMed
19.
Zurück zum Zitat Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC (2010) Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305–314. doi:10.1007/s10549-009-0350-0 CrossRefPubMed Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC (2010) Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305–314. doi:10.​1007/​s10549-009-0350-0 CrossRefPubMed
20.
Zurück zum Zitat Chew GL, Huang D, Lin SJ, Huo C, Blick T, Henderson MA, Hill P, Cawson J, Morrison WA, Campbell IG, Hopper JL, Southey MC, Haviv I, Thompson EW (2012) High and low mammographic density human breast tissues maintain histological differential in murine tissue engineering chambers. Breast Cancer Res Treat 135(1):177–187. doi:10.1007/s10549-012-2128-z CrossRefPubMed Chew GL, Huang D, Lin SJ, Huo C, Blick T, Henderson MA, Hill P, Cawson J, Morrison WA, Campbell IG, Hopper JL, Southey MC, Haviv I, Thompson EW (2012) High and low mammographic density human breast tissues maintain histological differential in murine tissue engineering chambers. Breast Cancer Res Treat 135(1):177–187. doi:10.​1007/​s10549-012-2128-z CrossRefPubMed
21.
Zurück zum Zitat Chew GL, Huang D, Huo CW, Blick T, Hill P, Cawson J, Frazer H, Southey MC, Hopper J, Henderson M, Haviv I, Thompson EW (2013) Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time. Breast Cancer Res Treat 140:285–297CrossRefPubMed Chew GL, Huang D, Huo CW, Blick T, Hill P, Cawson J, Frazer H, Southey MC, Hopper J, Henderson M, Haviv I, Thompson EW (2013) Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time. Breast Cancer Res Treat 140:285–297CrossRefPubMed
22.
Zurück zum Zitat Chew GL, Huo CW, Huang D, Blick T, Hill P, Cawson J, Frazer H, Southey MC, Hopper JL, Britt K, Henderson MA, Haviv I, Thompson EW (2014) Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers. Breast Cancer Res Treat 148(2):303–314. doi:10.1007/s10549-014-3169-2 CrossRefPubMed Chew GL, Huo CW, Huang D, Blick T, Hill P, Cawson J, Frazer H, Southey MC, Hopper JL, Britt K, Henderson MA, Haviv I, Thompson EW (2014) Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers. Breast Cancer Res Treat 148(2):303–314. doi:10.​1007/​s10549-014-3169-2 CrossRefPubMed
23.
Zurück zum Zitat BI-RADS (2003) BI-RADS. American College of Radiology, Reston BI-RADS (2003) BI-RADS. American College of Radiology, Reston
24.
Zurück zum Zitat Arteaga CL, Koli KM, Dugger TC, Clarke R (1999) Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 91(1):46–53CrossRefPubMed Arteaga CL, Koli KM, Dugger TC, Clarke R (1999) Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 91(1):46–53CrossRefPubMed
25.
Zurück zum Zitat Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M (2003) Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9(7):2651–2656PubMed Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M (2003) Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9(7):2651–2656PubMed
26.
Zurück zum Zitat Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55(6):429–434PubMedCentralCrossRefPubMed Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55(6):429–434PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Robertson FM, Mallery SR, Bergdall-Costell VK, Cheng M, Pei P, Prosperi JR, Ferrari M (2007) Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res 27(2):719–727PubMed Robertson FM, Mallery SR, Bergdall-Costell VK, Cheng M, Pei P, Prosperi JR, Ferrari M (2007) Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res 27(2):719–727PubMed
29.
Zurück zum Zitat Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB (2014) COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br J Cancer 111(1):46–54. doi:10.1038/bjc.2014.236 PubMedCentralCrossRefPubMed Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB (2014) COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br J Cancer 111(1):46–54. doi:10.​1038/​bjc.​2014.​236 PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Lin F, Luo J, Gao W, Wu J, Shao Z, Wang Z, Meng J, Ou Z, Yang G (2013) COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol 34(5):2817–2826. doi:10.1007/s13277-013-0840-x CrossRefPubMed Lin F, Luo J, Gao W, Wu J, Shao Z, Wang Z, Meng J, Ou Z, Yang G (2013) COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol 34(5):2817–2826. doi:10.​1007/​s13277-013-0840-x CrossRefPubMed
31.
Zurück zum Zitat Park BW, Park S, Park HS, Koo JS, Yang WI, Lee JS, Hwang H, Kim SI, Lee KS (2012) Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes. Breast Cancer Res Treat 133(2):741–751. doi:10.1007/s10549-012-1971-2 CrossRefPubMed Park BW, Park S, Park HS, Koo JS, Yang WI, Lee JS, Hwang H, Kim SI, Lee KS (2012) Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes. Breast Cancer Res Treat 133(2):741–751. doi:10.​1007/​s10549-012-1971-2 CrossRefPubMed
32.
Zurück zum Zitat Lyons TR, O’Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC, Schedin P (2011) Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17(9):1109–1115. doi:10.1038/nm.2416 PubMedCentralCrossRefPubMed Lyons TR, O’Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC, Schedin P (2011) Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17(9):1109–1115. doi:10.​1038/​nm.​2416 PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90(6):455–460CrossRefPubMed Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90(6):455–460CrossRefPubMed
34.
Zurück zum Zitat Davies G, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13(5):669–678CrossRefPubMed Davies G, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13(5):669–678CrossRefPubMed
35.
Zurück zum Zitat Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M (2011) Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 31(12):4359–4367PubMed Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M (2011) Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 31(12):4359–4367PubMed
36.
Zurück zum Zitat Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137(12):5739–5742. doi:10.1210/endo.137.12.8940410 PubMed Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137(12):5739–5742. doi:10.​1210/​endo.​137.​12.​8940410 PubMed
37.
Zurück zum Zitat Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140(1–2):27–35CrossRefPubMed Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140(1–2):27–35CrossRefPubMed
41.
Zurück zum Zitat Cotterchio M, Kreiger N, Sloan M, Steingart A (2001) Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomark Prev 10(11):1213–1217 Cotterchio M, Kreiger N, Sloan M, Steingart A (2001) Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomark Prev 10(11):1213–1217
42.
Zurück zum Zitat Brandao RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, Blok MJ, Keymeulen K, Ayoubi T, Smeets HJ, Tjan-Heijnen VC, Hupperets PS (2013) A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 15(2):R29. doi:10.1186/bcr3409 PubMedCentralCrossRefPubMed Brandao RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, Blok MJ, Keymeulen K, Ayoubi T, Smeets HJ, Tjan-Heijnen VC, Hupperets PS (2013) A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 15(2):R29. doi:10.​1186/​bcr3409 PubMedCentralCrossRefPubMed
43.
Zurück zum Zitat McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DS, Aiello Bowles EJ, White E, Rossing MA, Potter J, Urban N (2009) No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomark Prev 18(5):1524–1530. doi:10.1158/1055-9965.EPI-08-1088 CrossRef McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DS, Aiello Bowles EJ, White E, Rossing MA, Potter J, Urban N (2009) No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomark Prev 18(5):1524–1530. doi:10.​1158/​1055-9965.​EPI-08-1088 CrossRef
44.
46.
Zurück zum Zitat Terry MB, Buist DS, Trentham-Dietz A, James-Todd TM, Liao Y (2008) Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomark Prev 17(5):1088–1095. doi:10.1158/1055-9965.EPI-07-2836 CrossRef Terry MB, Buist DS, Trentham-Dietz A, James-Todd TM, Liao Y (2008) Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomark Prev 17(5):1088–1095. doi:10.​1158/​1055-9965.​EPI-07-2836 CrossRef
47.
Zurück zum Zitat Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496–503. doi:10.1016/S1470-2045(11)70030-4 CrossRefPubMed Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496–503. doi:10.​1016/​S1470-2045(11)70030-4 CrossRefPubMed
49.
Zurück zum Zitat Arun B, Goss P (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31(2 Suppl 7):22–29CrossRefPubMed Arun B, Goss P (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31(2 Suppl 7):22–29CrossRefPubMed
Metadaten
Titel
Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density
verfasst von
G. L. Chew
C. W. Huo
D. Huang
P. Hill
J. Cawson
H. Frazer
J. L. Hopper
I. Haviv
M. A. Henderson
K. Britt
E. W. Thompson
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3520-2

Weitere Artikel der Ausgabe 1/2015

Breast Cancer Research and Treatment 1/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.